



FOR IMMEDIATE RELEASE ON March 19, 2025

Flamma Awarded Best On-Time Delivery at 2025 CDMO Leadership Awards

Chignolo D'Isola, Bergamo, Italy – March 19, 2025 – The **Flamma Group** (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, received a 2025 CDMO Leadership Award that was presented in New York City on March 19, 2025.

Flamma was recognized as a 2025 CDMO Leadership Awards winner in the **Small Molecule API – Global** category. In addition to the CDMO Leadership Awards, Outsourced Pharma presented a Best In Class Award in order to capture more of what the CDMO industry and professionals excel at every day.

The Best In Class Award recognized additional qualities that innovator companies value when selecting a partner. Finalists and winners were calculated using the same survey results that support the Leadership Awards. **Flamma was named the winner of the Best On-Time Delivery category** over the other nominees Siegfried, WuXi Biologics, and WuXi STA.

You can learn more as well as see the other award winners at <https://www.cdmoleadershipawards.com>

“Flamma is delighted to be recognized for not only its CDMO Leadership Award in the Small Molecule API- Global category but to also be selected for a Best In Class award for On-Time Delivery shows the industry how dedicated we are to service our customers. We strive to provide fair quotes with realistic delivery times in order to illustrate our commitment to the customer,” said Kenneth Drew, Ph.D., VP Flamma USA. “This is a testament to our employees who are the reason we are successful. Flamma is proud to be celebrating 75 years of industry service. We endeavor to be the CDMO that pharmaceutical and biotech companies can depend on for quality service and delivery of their small molecule”.

Flamma accepted these awards at the CDMO Leadership Awards Ceremony and Reception on March 19, 2025 at the POOL in New York City.



Contact Flamma
Kenneth Drew, Ph.D., VP Flamma USA
1-617-515-0975
ken.drew@flammagroup.com

About Flamma:

FLAMMA is a family owned & run, fully integrated CDMO based in Bergamo (near Milan in Northern Italy) established in 1950.

FLAMMA is a company specialized in the cGMP manufacture of small molecule APIs, NCEs, RSMs, and advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries and has several generic products.

FLAMMA has five manufacturing facilities- Italy (3), China, and the USA. The cGMP Italian locations (Chignolo, Isso and Bulciago) are regularly inspected by the FDA and AIFA. Flamma Honkai, located in Dalian, China, is a cGMP manufacturing facility that has been inspected by Chinese National Medical Products Administration (NMPA) formally known as the Chinese FDA. Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma reliably supplies materials directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver the customer's compound on-time and with the desired specifications. Flamma offers cost-effective services to customers looking for a trusted partner within China.

Flamma USA (Malvern, PA near Philadelphia) services customers looking to keep their pre-clinical/early stage clinical small molecule drug development in the USA. Flamma USA also offers the ability to handle HPAPIs as well as low volume commercial materials.

As a fully integrated company, Flamma can move customer compounds quickly along their journey by taking into consideration all aspects necessary for the success of customer's projects while providing supply chain security.

Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 1,100 m³ and over ~1,000 employees, see why Flamma should be your next contract manufacturer.

FLAMMA - THE THINKING CDMO™.



<https://www.flammagroup.com/>

<https://www.linkedin.com/company/flamma-spa/>

<https://twitter.com/flammagroup>

<https://www.facebook.com/TheFlammaGroup/>